Patents by Inventor Rolf Hartmann
Rolf Hartmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230331403Abstract: A method for determining the position of a spacecraft in space, includes cyclically÷ repeating steps of capturing distorted star images; processing the distorted star images to form distorted star group data; storing the distorted star group data; determining a current rotation rate by comparing the distorted star group data of two consecutive cycles; transmitting the current rotation rate to a position control system; and/or the following steps are carried out: processing the distorted star images of a current cycle to form rectified star group data; determining position information by matching the rectified star group data with star group catalog data which is carried along; transmitting the position information to the position control system. A method for determining the position of a spacecraft in space, taking into account known system parameters of an optical system, includes: coding star group catalog data with n = 3...Type: ApplicationFiled: August 23, 2021Publication date: October 19, 2023Applicant: JENA-OPTRONIK GMBHInventors: Uwe Schmidt, Falk Ahlendorf, Rolf Hartmann
-
Patent number: 10519099Abstract: The present invention provides a method for the treatment or prophylaxis of bacterial infections by administering to a subject in need thereof an effective amount of a compound of formula.Type: GrantFiled: November 26, 2015Date of Patent: December 31, 2019Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBHInventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
-
Patent number: 9884839Abstract: Provided herein are non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 and type 2 (17?-HSD1 and 17?-HSD2) inhibitors, their production and use, especially for the treatment and for prophylaxis of hormone-related diseases.Type: GrantFiled: January 5, 2015Date of Patent: February 6, 2018Assignee: ElexoPharm GmbHInventors: Rolf Hartmann, Martin Frotscher, Ahmed Saad Abdelsamie Ahmed, Emmanuel Bey, Chris J. van Koppen, Sandrine Oberwinkler-Marchais, Carsten Börger, Lorenz Siebenbürger, Victor Hernández Olmos
-
Publication number: 20170327458Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.Type: ApplicationFiled: November 26, 2015Publication date: November 16, 2017Applicant: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBHInventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
-
Patent number: 9745282Abstract: This invention relates to indoline compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: June 30, 2016Date of Patent: August 29, 2017Assignees: Merck Sharp & Dohme Corp, ElexoPharm GmbHInventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
-
Patent number: 9550750Abstract: This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: October 2, 2013Date of Patent: January 24, 2017Assignees: Merck Sharp & Dohme Corp., Elexopharm GMBHInventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
-
Publication number: 20160318895Abstract: Provided herein are non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 and type 2 (17?-HSD1 and 17?-HSD2) inhibitors, their production and use, especially for the treatment and for prophylaxis of hormone-related diseases.Type: ApplicationFiled: January 5, 2015Publication date: November 3, 2016Inventors: Rolf Hartmann, Martin Frotscher, Ahmed Saad Abdelsamie Ahmed, Emmanuel Bey, Chris J. van Koppen, Sandrine Oberwinkler-Marchais, Carsten Börger, Lorenz Siebenbürger, Victor Hernández Olmos
-
Publication number: 20160304486Abstract: This invention relates to indoline compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: ApplicationFiled: June 30, 2016Publication date: October 20, 2016Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
-
Patent number: 9394290Abstract: The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.Type: GrantFiled: October 21, 2011Date of Patent: July 19, 2016Assignee: UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKENInventors: Rolf Hartmann, Ulrike Hille, Christina Zimmer, Carsten A. Vock, Qingzhong Hu
-
Publication number: 20160145304Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections:Type: ApplicationFiled: July 14, 2014Publication date: May 26, 2016Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf Hartmann, Mostafa Hamed, Walid A.M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning
-
Patent number: 9296495Abstract: A hybrid network of kinematic sensors of an AOCS, made up of a star sensor including an optical camera head, and a processing unit provided as the central master processing unit, and additional kinematic sensors, each made up of a sensor element and a processing unit connected to the central processing unit via a first bus. An additional processing unit is equivalent to the processing unit and is a redundant central processing unit. The central processing units and—are connected via an additional bus of a spacecraft provided with the hybrid network with the aid of a central computer. The particular active central processing units-provide all kinematic sensors with a uniform time pulse via a synchronization line, and supply the central computer with hybridized kinematic measuring data formed according to a method for hybridization based on the synchronous kinematic measuring data of the star sensor and the measuring data of the other sensors.Type: GrantFiled: August 7, 2014Date of Patent: March 29, 2016Assignee: JENA OPTRONIK GMBHInventors: Rolf Hartmann, Dieter Schoedlbauer, Uwe Schmidt
-
Patent number: 9278093Abstract: This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.Type: GrantFiled: March 29, 2013Date of Patent: March 8, 2016Assignees: Merck Sharp & Dohme Corp., ElexoPharm GmbHInventors: Amjad Ali, Emmanuel Bey, Rolf Hartmann, Quingzhong Hu, Lina Yin
-
Patent number: 9271963Abstract: The invention relates to compounds for selectively inhibiting human corticosteroid synthases CYP1 1 B1 and CYP1 1 B2, and to the production and use thereof for treating hypercortisolism, diabetes mellitus, hyperaldosteronism, cardiac insufficiency, myocardial fibrosis, depression, age-related cognitive decline and metabolic syndrome.Type: GrantFiled: March 2, 2006Date of Patent: March 1, 2016Assignee: UNIVERSITAT DES SAARLANDESInventors: Rolf Hartmann, Marieke Voets, Ursula Müller-Vieira
-
Publication number: 20160023552Abstract: A center console arrangement for a motor vehicle includes a housing arrangement with at least one cover surface arranged thereon. The cover surface includes at least two functional regions. Each functional regions includes at least one display and/or operator control panel. Each of the display and/or operator control panels is assigned, with respect to functionality, to the corresponding functional region.Type: ApplicationFiled: February 22, 2014Publication date: January 28, 2016Inventors: Thomas MIM, Lutz KRAUSS, Alexander BOGNER, Franz-Josef SIEGERT, Anke WILHELM, Rolf HARTMANN
-
Publication number: 20150306091Abstract: This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.Type: ApplicationFiled: March 29, 2013Publication date: October 29, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Emmanuel Bey, Rolf Hartmann, Quingzhong Hu, Lina Yin
-
Patent number: 9107675Abstract: A device for in situ milling of joint surfaces, including a milling device and a joint clamping device. The joint clamp device is designed to be inserted between two joint components forming a joint, particularly bones, and for pushing the joint components apart with a predetermined or adjustable tension, wherein the joint clamping device includes a recess in which the milling device can be inserted, wherein the milling device includes a face milling cutter.Type: GrantFiled: June 16, 2010Date of Patent: August 18, 2015Assignee: UNIVERSITÄT ROSTOCKInventors: Attila Vasarhelyi, Rolf Hartmann
-
Publication number: 20150225365Abstract: This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: ApplicationFiled: October 2, 2013Publication date: August 13, 2015Applicants: ElexoPharm GmbH, Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
-
Patent number: 9073929Abstract: This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.Type: GrantFiled: April 20, 2012Date of Patent: July 7, 2015Assignees: ElexoPharm GmbH, Merck Sharp & Dohme Corp.Inventors: Scott B. Hoyt, Whitney Lane Petrilli, Clare London, Yusheng Xiong, Jerry Andrew Taylor, Amjad Ali, Michael Man-Chu Lo, Timothy J. Henderson, Qingzhong Hu, Rolf Hartmann, Lina Yin, Ralf Heim, Emmanuel Bey, Rohit Saxena, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Patent number: 9073568Abstract: A display and operating system of a motor vehicle includes an instrument cluster that is formed by a plurality of display devices and has an outer left-hand display device and an outer right hand display device. A steering wheel of the system includes an outer left-hand operating device configured exclusively for driver interaction with the outer left-hand display device of the instrument cluster and an outer right-hand operating device configured exclusively for driver interaction with the outer right-hand display device of the instrument cluster. Further devices, including at least one of a display device or an operating device, are disposed laterally adjacent to the instrument cluster.Type: GrantFiled: December 18, 2010Date of Patent: July 7, 2015Assignee: DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFTInventors: Lutz Krauss, Timo Seehaus, Rolf Hartmann, Albrecht Boettiger, Thomas Mim
-
Publication number: 20150041595Abstract: A hybrid network of kinematic sensors of an AOCS, made up of a star sensor including an optical camera head, and a processing unit provided as the central master processing unit, and additional kinematic sensors, each made up of a sensor element and a processing unit connected to the central processing unit via a first bus. An additional processing unit is equivalent to the processing unit and is a redundant central processing unit. The central processing units and—are connected via an additional bus of a spacecraft provided with the hybrid network with the aid of a central computer. The particular active central processing units-provide all kinematic sensors with a uniform time pulse via a synchronization line, and supply the central computer with hybridized kinematic measuring data formed according to a method for hybridization based on the synchronous kinematic measuring data of the star sensor and the measuring data of the other sensors.Type: ApplicationFiled: August 7, 2014Publication date: February 12, 2015Inventors: Rolf Hartmann, Dieter Schoedlbauer, Uwe Schmidt